

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Shendelman Shoshana</u> (Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 (Street) NEW YORK NY 10017 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Applied Therapeutics Inc. [APLT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) President and CEO
	3. Date of Earliest Transaction (Month/Day/Year) 07/20/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/20/2020		M		15,000 ⁽¹⁾	A	\$1.44	569,285	D	
Common Stock	07/20/2020		S		12,100 ⁽²⁾	D	\$27.19 ⁽³⁾	557,185	D	
Common Stock	07/20/2020		S		2,600 ⁽²⁾	D	\$27.88 ⁽⁴⁾	554,585	D	
Common Stock	07/20/2020		S		300 ⁽²⁾	D	\$28.64	554,285	D	
Common Stock	07/21/2020		M		15,000 ⁽¹⁾	A	\$1.44	569,285	D	
Common Stock	07/21/2020		S		7,600 ⁽²⁾	D	\$26.69 ⁽⁵⁾	561,685	D	
Common Stock	07/21/2020		S		7,300 ⁽²⁾	D	\$27.42 ⁽⁶⁾	554,385	D	
Common Stock	07/21/2020		S		100 ⁽²⁾	D	\$28.24	554,285	D	
Common Stock	07/22/2020		M		15,000 ⁽¹⁾	A	\$1.44	569,285	D	
Common Stock	07/22/2020		S		12,051 ⁽²⁾	D	\$25.45 ⁽⁷⁾	557,235	D	
Common Stock	07/22/2020		S		2,949 ⁽²⁾	D	\$26.51 ⁽⁸⁾	554,285	D	
Common Stock								1,750,000	I	See footnote ⁽⁹⁾
Common Stock								88,397	I	See footnote ⁽¹⁰⁾
Common Stock								1,492,094	I	See footnote ⁽¹¹⁾
Common Stock								290,280	I	See footnote ⁽¹²⁾
Common Stock								709,720	I	See footnote ⁽¹³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$1.44	07/20/2020		M			15,000 ⁽¹⁾	(14)	03/07/2028	Common Stock	15,000	\$0.00	569,609	D	
Stock Option (Right to Buy)	\$1.44	07/21/2020		M			15,000 ⁽¹⁾	(14)	03/07/2028	Common Stock	15,000	\$0.00	554,609	D	
Stock Option (Right to Buy)	\$1.44	07/22/2020		M			15,000 ⁽¹⁾	(14)	03/07/2028	Common Stock	15,000	\$0.00	539,609	D	

Explanation of Responses:

1. Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's previously disclosed written trading plan with Goldman Sachs & Co. LLC, dated May 28, 2020, filed as Exhibit 99.4 to Amendment No. 1 to the reporting person's Schedule 13D, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. Sales made pursuant to the reporting person's previously disclosed written trading plan with Goldman Sachs & Co. LLC, dated May 28, 2020, filed as Exhibit 99.4 to Amendment No. 1 to the reporting person's Schedule 13D, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
3. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.6200 to \$27.6100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
4. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$27.6200 to \$28.3600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
5. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.2000 to \$27.0150 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
6. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$27.0200 to \$28.1700 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
7. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$25.0500 to \$26.0400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
8. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.0500 to \$26.9600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
9. Through a grantor retained annuity trust.
10. Through Clearpoint Strategy Group LLC of which the reporting person is the sole owner.
11. Through a family trust controlled by the reporting person's spouse.
12. Through a family trust controlled by the reporting person.
13. Through the reporting person's spouse.
14. These options became fully vested on March 7, 2020.

Remarks:

Following the exercise of options and sale of shares of common stock as described in this Form 4, the reporting person continues to own, directly or indirectly, 4,884,776 shares of common stock and options to purchase 2,488,169 shares of common stock, representing an ownership interest in the Issuer of approximately 21.8% and approximately 27.7% on an actual and fully-diluted basis, respectively, as of the date of this Form 4.

/s/ Shoshana Shendelman

07/22/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.